|Articles|September 23, 2022
Antibody-based drug discovery at the speed of light
Author(s)Curia
The combination of the PentaMice® platform and single B cell screening with the Beacon® system increases speed to market for monoclonal antibody antibody therapeutics.
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Related Content
Trending on BioPharm International
1
Neurimmune and AstraZeneca Expand Efforts to Accelerate Fibril-Depleting Therapies
2
New Draft Guidance Highlights FDA Push Toward Human-Relevant Safety Models
3
Regulatory Uncertainty Surfaces as FDA Blames COVID Vaccines for 10 Child Deaths
4
New Lymphoma Indication for CAR T-Cell Therapy Shapes Pipeline
5
